Neuroendocrine tumour management: A team approach

Hospital Medicine

Volumn 66, Issue 1, 2005, Pages 37-42

  Banfield, A ^a   Green, S ^a   Ramage, J K ^a,b,c,d  

^a NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Novartis Pharmaceuticals UK   (United Kingdom)

^d IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; DIAZOXIDE; GLUCAGON; SOMATOSTATIN ANALOG; VASOACTIVE INTESTINAL POLYPEPTIDE ANTIBODY;

ARTIFICIAL EMBOLISM; BEAM THERAPY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; GASTRINOMA; GLUCAGONOMA; GLUCOSE INFUSION; HISTOPATHOLOGY; HUMAN; INSULINOMA; MEDICAL ASSESSMENT; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PROGNOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; VIPOMA; WORLD HEALTH ORGANIZATION;

EID: 13444291219     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2005.66.1.17534     Document Type: Review

References (31)

1. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-76
2. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM (2000) Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95(9): 2271-7
3. Bax ND, Woods HF, Batchelor A, Jennings M (1996) Clinical manifestations of carcinoid disease. World J Surg 20(2): 142-6
4. Beasley MB, Thunnissen FB, Brambilla E et al (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31(10): 1255-65
5. Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12): 5658-71
6. Brandle M, Pfammatter T, Spinas GA, Lehmann R, Schmid C (2001) Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf) 55(3): 357-62
7. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4): 432-45
8. Davies AG, Ramage JK on behalf of UKNET (2005) Guidelines for management of gastrointestinal and pancreatic neuroendocrine tumours (including carcinoid). Gut (in press)
9. Faiss S, Scherubl H, Riecken EO, Wiedenmann B (1996) The ultimate biochemical diagnosis of neuroendocrine gastroenteropancreatic tumours. Digestion 57(Suppl 1): 48-9
10. Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21(14): 2689-96
11. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O (2002) Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardio-Thorac Surg 21(5): 913-17
12. Gentil PA, Mosnier JF, Buono JP et al (1998) The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 109(3): 286-93
13. Gibril F, Schumann M, Pace A, Jensen RT (2004) Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83(1): 43-83
14. Goede AC, Caplin ME, Winslet MC (2003) Carcinoid tumour of the appendix. Br J Surg 90(11): 1317-22
15. Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg K (1998) Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 43(2): 223-8
16. Hemminki K, Li X (2001a) Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 94(3): 444-8
17. Hemminki K, Li X (2001 b) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92(8): 2204-10
18. Kloppel G, Heitz PU, Capella C, Solcia E (2000) Endocrine tumours of the pancreas. In: Solcia E, Kloppel G, Sobin J, eds. Histological Typing of Endocrine Tumours. Springer-Verlag, Berlin: 56-60
19. Krenning EP, Kwekkeboom DJ, Oei HY et al (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion 55(Suppl 3): 54-9
20. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C (2000) Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 83(7): 952-5
21. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97(4): 934-59
22. Modlin IM, Lye KD, Kidd M (2004) A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 99(1): 23-32
23. Moertel CG, Kvols LK, Rubin J (1991) A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67(1): 33-6
24. Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15(6): 966-73
25. O'Briain DS, Dayal Y, DeLellis RA, Tischler AS, Bendon R, Wolfe HJ (1982) Rectal carcinoids as tumors of the hindgut endocrine cells: a morphological and immunohistochemical analysis. Am J Surg Pathol 6(2): 131-42
26. Ramage JK, Davies AH (2003) Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer 10(4): 483-6
27. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E (1996) Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20(2): 168-72
28. Ruszniewski P, Rougier P, Roche A et al (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71(8): 2624-30
29. Solcia E, Capella C, Kloppel G, Heitz PU, Sobin L, Rosa J (2000) Endocrine tumours of the gastrointestinal tract. In: Solcia E, Kloppel G, Sobin J, eds. Histological Typing of Endocrine Tumours. Springer-Verlag, Berlin: 61-8
30. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R (2001) Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 12(Suppl 2): S95-S99
31. Wermers RA, Fatourechi V, Kvols LK (1996) Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 71(11): 1030-8